Berlin Cures Welcomes Renowned Immunologist Professor Danny Altmann to its Advisory Board

Berlin, Germany, 29 August 2024 – Berlin Cures, a biotechnology company in Phase II clinical trials for a treatment against Long COVID and other autoimmune diseases, has appointed Professor Danny Altmann to its Advisory Board. Altmann, an immunologist from Imperial College London, will bring his expertise to the company’s drug research and development, particularly concerning autoimmune diseases and Long COVID.

The Advisory Board advises Berlin Cures on industry developments, explores growth opportunities, and supports new therapy market launches. "We are thrilled to welcome Professor Altmann," said Oliver von Stein, CEO of Berlin Cures. "His expertise in immunology, especially regarding SARS-CoV-2's long-term effects, makes him a perfect addition."

Professor Altmann has been influential throughout the COVID-19 pandemic, advising various policy makers and organizations. He currently leads a research project on the long-term immunological effects of SARS-CoV-2 and is a trustee at the British organization Long COVID support.

Berlin Cures is conducting a Phase II clinical trial with its drug candidate BC 007 (Rovunaptabin) in Long COVID patients, with initial results expected in Q4 2024. The company is seeking financial partners for a potential Phase III trial following positive Phase II outcomes.